March 2, 2018 10:24 AM EST

EpimAb nabs Bin Peng from NIBR; Jeffrey Chodakewitz exits Vertex; Christiana Stamoulis is president at Unum

Amber Tong

→ Christiana Stamoulis is getting busier at Unum Therapeutics as she adds the role of president to her CFO and head of corporate development …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EpimAb nabs Bin Peng from NIBR; Jeffrey Chodakewitz exits Vertex; Christiana Stamoulis is president at Unum

Amber Tong

Sign up to read this article for free.

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals

EpimAb nabs Bin Peng from NI­BR; Jef­frey Chodake­witz ex­its Ver­tex; Chris­tiana Sta­moulis is pres­i­dent at Unum

Amber Tong

Sign up to read this article for free.

more like this

Biose­cure com­pro­mise could add ex­ec­u­tive re­view process for named com­pa­nies, sources say

Af­ter Unit­ed­Health­care CEO killing, health­care in­dus­try faces a new se­cu­ri­ty re­al­i­ty

Eli­av Barr de­fends Mer­ck­'s LaNo­va deal, but cau­tions VEGF bis­pecifics have yet to de­liv­er ma­ture da­ta

Lil­ly con­tin­ues to ex­pand its em­pire of GLP-1 fac­to­ries with new $3B build­out

GSK's third new pact of the week fo­cus­es on Alzheimer's with start­up Mu­na Ther­a­peu­tics

FDA spells out new ex­pe­dit­ed with­draw­al pro­ce­dures for ac­cel­er­at­ed ap­provals

EpimAb nabs Bin Peng from NIBR; Jeffrey Chodakewitz exits Vertex; Christiana Stamoulis is president at Unum

Biosecure compromise could add executive review process for named companies, sources say

After UnitedHealthcare CEO killing, healthcare industry faces a new security reality

Eliav Barr defends Merck's LaNova deal, but cautions VEGF bispecifics have yet to deliver mature data

Lilly continues to expand its empire of GLP-1 factories with new $3B buildout

GSK's third new pact of the week focuses on Alzheimer's with startup Muna Therapeutics

FDA spells out new expedited withdrawal procedures for accelerated approvals